Hematologic, biochemical, and cardiopulmonary effects of l‐arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy
- 19 February 2009
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 82 (4), 315-321
- https://doi.org/10.1111/j.1600-0609.2009.01210.x
Abstract
Objectives: Fetal hemoglobin (HbF) induction involves NO‐cGMP signaling pathways. l‐arginine, an NO precursor, and the phosphodiesterase (PDE) 5 inhibitor sildenafil, which potentiates cGMP, were studied in adults with sickle cell disease (SCD) who were stably on HU. Methods: Twenty four courses of l‐arginine (0.1–0.2 g/kg divided TID) or sildenafil (25–100 mg TID), assigned based on gender due to concerns about sildenafil‐related priapism, were successfully completed. Biochemical assays, pulmonary pressures, and cardiopulmonary exercise capacity are reported from patients in whom serial values are available. Hematologic responses are reported in 14 subjects with HbSS who had stable baseline HbF levels. Results: l‐arginine increased plasma arginine and ornithine, but not citrulline, suggesting diversion by plasma arginase from NO, and citrulline, generation. Glutathione increased only in patients on l‐arginine. Sildenafil increased plasma cGMP and citrulline, but not other amino acids. Pulmonary pressures and 6‐min walk distances improved only in patients on sildenafil. In subjects with stable baseline HbF levels, HbF levels changed little from a normalized baseline on l‐arginine, decreasing by 2.9 ± 16.1%, n = 6; P = n.s., but increased on sildenafil, by 7.5 ± 11.7%, n = 8, P < 0.05. Absolute reticulocyte counts initially decreased in patients on sildenafil. Conclusions: l‐arginine, at doses that increase plasma arginine levels, altered redox potential in red cells. The lack of clinically detectable efficacy of l‐arginine may be due to increased arginine metabolism in SCD patients. In vivo augmentation of the cyclic nucleotide pathway by PDE inhibition may induce HbF slightly, but strikingly improves hemodynamic and functional status in SCD.Keywords
This publication has 35 references indexed in Scilit:
- Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell diseaseBlood, 2008
- Hemodynamic and Functional Assessment of Patients with Sickle Cell Disease and Pulmonary HypertensionAmerican Journal of Respiratory and Critical Care Medicine, 2007
- Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyureaThe Pharmacogenomics Journal, 2007
- Protective effect of arginine on oxidative stress in transgenic sickle mouse modelsFree Radical Biology & Medicine, 2006
- Feasibility of the Use of Phosphodiesterase Type 5 Inhibitors in a Pharmacologic Prevention Program for Recurrent PriapismThe Journal of Sexual Medicine, 2006
- Role of Cyclic Nucleotides in Fetal Hemoglobin Induction in Cultured CD34+ CellsExperimental Hematology, 2006
- Hemolysis‐Associated Pulmonary Hypertension in ThalassemiaAnnals of the New York Academy of Sciences, 2005
- Increased levels of soluble ICAM‐1 in the plasma of sickle cell patients are reversed by hydroxyureaAmerican Journal of Hematology, 2004
- Negative regulation of γ-globin gene expression by cyclic AMP-dependent pathway in erythroid cellsExperimental Hematology, 2004
- Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell AnemiaThe New England Journal of Medicine, 1995